EditorialImproved survival and reduced stroke risk in patients with atrial fibrillation: Is catheter ablation winning the rhythm-control race?
Section snippets
Editorial
Atrial fibrillation (AF) is the most common cardiac arrhythmia and is associated with increased thromboembolic risk and mortality [1]. Catheter ablation as a strategy in managing this complex arrhythmia is generally reserved for symptomatic patients who are intolerant or refractory to anti-arrhythmic drugs for symptom control [2]. Indeed, catheter ablation has been repeatedly shown to be effective in improving symptom control and quality of life although the lack of “hard” endpoints to date is
Acknowledgements
Financial disclosures: Dr. Kadhim is supported by a Leo J. Mahar Scholarship from the University of Adelaide. Dr. Lau is supported by the Robert J. Craig Lectureship from the University of Adelaide. Dr. Linz is supported by a Beacon Fellowship from the University of Adelaide. Dr. Sanders is supported by Practitioner Fellowships from the NHMRC and NHF of Australia.
Conflict of interest disclosures
Dr. Linz reports having served on the advisory board of LivaNova and Medtronic. Dr. Linz reports having received lecture and/or consulting fees from LivaNova, Medtronic, Pfizer and ResMed. Dr. Linz reports having received research funding from Sanofi, ResMed and Medtronic. Dr. Sanders reports having served on the advisory board of Biosense-Webster, Medtronic, Abbott, Boston Scientific and CathRx. Dr. Sanders reports thet the University of Adelaide receives on his behalf lecture and/or
References (11)
- et al.
HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation
Heart Rhythm
(2017) - et al.
Association of catheter ablation for atrial fibrillation with mortality and stroke: a systematic review and meta-analysis
Int J of Cardiol.
(2018) - et al.
Catheter ablation versus antiarrhythmic drug therapy for atrial fibrillation (CABANA) trial: study rationale and design
Am. Heart J.
(2018) - et al.
The optimal anti-coagulation for enhanced risk patients post-catheter ablation for atrial fibrillation (OCEAN) trial
Am. Heart J.
(2018) - et al.
Impact of atrial fibrillation on the risk of death: the Framingham Heart Study
Circulation
(1998)
Cited by (3)
Long-term efficacy and safety of anticoagulation after atrial fibrillation ablation: data from the JACRE registry
2021, Journal of CardiologyCitation Excerpt :Therefore, our study possibly reflected the efficacy and safety of OAC after CA from a different perspective. Although meta-analysis of cohort studies suggested that AF ablation may reduce stroke risk [14], no randomized trials to investigate this hypothesis have been performed, possibly due to the estimated very large sample size needed, and the efficacy of stroke prevention by AF ablation has not been established [15]. The incidence rate of ischemic stroke in Japanese patients with AF taking DOAC was reported to be 1.34% per patient-year in the SAKURA AF registry (CHADS2 and CHA2DS2-VASc scores, 1.72 ± 1.14 and 2.92 ± 1.46, respectively).
Science deserves justice: The results of the CABANA trial are positive and support catheter ablation of atrial fibrillation for reducing mortality and hospitalizations
2019, Revista Portuguesa de CardiologiaCitation Excerpt :This effect became more pronounced in sub-analyses of studies including only heart failure patients.8,9 Several factors have been suggested to explain the benefit of AF ablation in patients with heart failure, which are discussed in more detail by Kadhim et al.10 Statistical considerations concerning this subject are discussed in Box II. Figure 1 shows the effect size, represented by the NNT, of several drugs and interventions currently used in cardiovascular medicine and recommended in international guidelines.
Catheter ablation of atrial fibrillation in patients with heart failure with reduced ejection fraction: Real world experience from six European centers
2019, Journal of Cardiovascular Electrophysiology